RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Clinical trials for RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM trials appear
Sign up with your email to follow new studies for RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new pill called onvansertib for people with specific blood cancers (CMML or MDS/MPN) that have returned or stopped responding to other treatments. The drug works by blocking a protein that helps cancer cells grow. The main goals are to find the best…
Matched conditions: RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 02:57 UTC
-
New Triple-Drug cocktail targets tough leukemia mutations
Disease control Recruiting nowThis study is for people with certain blood cancers (acute myeloid leukemia, chronic myelomonocytic leukemia, or high-risk myelodysplastic syndrome) that have a specific genetic change called a FLT3 mutation. The cancer has either come back or not responded to prior treatment. Th…
Matched conditions: RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for rare blood cancers: drug combo trial launches
Disease control Recruiting nowThis study tests a new antibody drug (axatilimab) with or without a chemotherapy-like drug (azacitidine) in people with advanced blood cancers like MPN, MPN/MDS overlap, or high-risk CMML. The goal is to find the best dose and see if the combination can shrink or control the canc…
Matched conditions: RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1, PHASE2 • Sponsor: Uma Borate • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Metal detox may boost chemo for blood cancer patients
Symptom relief Recruiting nowThis early-phase study tests whether two metal-removing drugs (edetate calcium disodium and succimer) are safe and can help control acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) when given alongside chemotherapy. About 58 adults with these blood cancers will rece…
Matched conditions: RECURRENT MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated May 17, 2026 02:44 UTC